Chapter 35 — Key Takeaways

What you should leave Chapter 35 with

  1. Drug discovery is a 10-15 year, $1-3 billion process integrating chemistry, biology, pharmacology, statistics, and regulatory science.

  2. Aspirin's mechanism is irreversible covalent acetylation of COX's Ser530 — a textbook example of nucleophilic acyl substitution (Ch 26) applied to medicine. The acetyl group is transferred from aspirin's ester to the serine OH; salicylate is the leaving group.

  3. Aspirin's clinical uniqueness: its irreversible mechanism gives long-lasting platelet COX inhibition (~10 days, the platelet's lifetime). Low-dose aspirin (81 mg/day) is uniquely effective for cardiovascular prevention.

  4. Ibuprofen is a reversible competitive COX inhibitor. The (S)-enantiomer is active. Anti-inflammatory + analgesic, but no cardiovascular benefit (no irreversible platelet inhibition).

  5. Acetaminophen weakly inhibits CNS COX. Mostly analgesic + antipyretic. Toxic at overdose via NAPQI (a Michael acceptor) that depletes glutathione and modifies liver proteins. Treated with N-acetylcysteine.

  6. Lipinski's Rule of 5 (oral drug-like properties): - MW ≤ 500. - logP ≤ 5. - H-bond donors ≤ 5. - H-bond acceptors ≤ 10. - Compounds violating ≥2 rules tend to have poor oral bioavailability. Heuristic, not absolute.

  7. SAR (Structure-Activity Relationship) is the systematic optimization of a hit compound by making analogs and measuring activity. Each modification tests one structural feature's contribution to potency, selectivity, or ADME.

  8. Bioisosteres are structural replacements that preserve biology but change chemistry. Common swaps: - COOH ↔ tetrazole (similar acidity; tetrazole more metabolically stable). - OH ↔ NH₂ (both H-bond donors; different basicity). - CH= ↔ N= (in aromatic rings; changes basicity). - Ester ↔ amide (similar geometry; amide more stable). - Phenyl ↔ pyridyl (additional H-bond acceptor).

  9. Prodrugs are inactive compounds metabolized to active drugs. Used to: - Improve oral bioavailability (mask polar groups). - Increase plasma half-life. - Target specific tissues. - Examples: enalapril → enalaprilat (ester prodrug), valacyclovir → acyclovir, L-DOPA → dopamine.

  10. Pharmacokinetics (PK) = what the body does to the drug (ADME). Pharmacodynamics (PD) = what the drug does to the body. Both must be balanced for a successful drug.

  11. CYP3A4 is the major drug-metabolizing enzyme. Drug-drug interactions via CYP3A4 inhibition are common clinical concerns.

  12. Covalent inhibitors are having a renaissance. Examples:

    • Aspirin (acetyl transfer to serine).
    • Ibrutinib (acrylamide thia-Michael to Cys481 of BTK).
    • Sotorasib (thia-Michael to K-Ras G12C cysteine).
    • Afatinib, osimertinib (acrylamide thia-Michael to EGFR Cys797).

  13. Thalidomide arc (1957-2024+):

    • 1957-1961: causes 10,000 cases of phocomelia.
    • 1961: withdrawn.
    • 1990s: lenalidomide (an analog) approved for multiple myeloma.
    • 2010: cereblon identified as the thalidomide target.
    • 2015+: PROTACs designed using thalidomide-derived cereblon ligands.

  14. PROTACs (proteolysis-targeting chimeras) are heterobifunctional drugs:

    • Target ligand: binds disease-causing protein.
    • Linker: connects the two ligands (typically alkyl or PEG).
    • E3 ligase ligand: binds cereblon (most commonly).

  15. PROTAC mechanism: target-PROTAC-E3 ternary complex → polyubiquitination → proteasomal degradation. Catalytic (one PROTAC degrades many target molecules).

  16. PROTAC advantages over inhibitors:

    • Can target "undruggable" proteins (transcription factors).
    • Can overcome drug resistance.
    • Catalytic, allowing low doses.
    • Tissue-selective via E3 ligase choice.

  17. PROTAC challenges:

    • Linker design (length, flexibility).
    • Cell penetration (PROTACs are larger than Lipinski-compliant).
    • Hook effect (saturation reduces ternary complex).
    • Off-target degradation.

  18. Clinical PROTACs (2024): ARV-471 (ER+ breast cancer), ARV-110 (prostate cancer), BTK PROTACs (overcoming ibrutinib resistance), neurodegenerative PROTACs (tau, α-synuclein).

  19. AI is transforming drug discovery in target identification, virtual screening, ADME prediction, retrosynthesis, and clinical trial design. The 10-15 year cycle may shrink to 3-5 years in the coming decade.

  20. Mastery of Chapter 35 integrates:

    • Chapter 3 (acid/base, pKa for ionization at physiological pH).
    • Chapter 7 (chirality and enantiomer-specific activity).
    • Chapter 24-30 (carbonyl chemistry; covalent drug warheads).
    • Chapter 32-34 (biology and biosynthesis as drug targets).
    • Chapter 31 (synthesis design).

This chapter closes Part VII. Part VIII turns to advanced topics: oxidation/reduction (Ch 36), organometallic chemistry (Ch 37), the art of synthesis (Ch 38), pericyclic reactions (Ch 39), and green chemistry / future of organic synthesis (Ch 40).

Cross-references

  • Chapter 1 — Introduces aspirin/ibuprofen/acetaminophen anchor examples.
  • Chapter 7 — Stereochemistry; thalidomide enantiomer effects.
  • Chapter 24 — Carbonyl group; reactivity ordering relevant to covalent drugs.
  • Chapter 25-26 — Nucleophilic addition and acyl substitution; aspirin mechanism.
  • Chapter 27 — α-Carbon chemistry; thalidomide racemization.
  • Chapter 29 — Michael addition; covalent drug warheads.
  • Chapter 30 — Amines; most drugs contain amines.
  • Chapter 31 — Synthesis Workshop 2; retrosynthetic analysis.
  • Chapter 32-34 — Biological molecules as drug targets.
  • Appendix B — pKa table.
  • Appendix F — Named reactions: SPPS, DCC coupling, etc.

Study tip

For each drug you encounter, ask: 1. What is the target? (A specific protein, ideally.) 2. What is the mechanism? (Reversible/irreversible? Covalent/non-covalent? At what site?) 3. What chemistry is involved? (Nucleophilic acyl substitution? Michael addition? PROTAC-style degradation?) 4. What ADME challenges exist? (Lipinski compliance? Metabolic stability? Cell penetration?)

If you can answer these for aspirin, ibuprofen, acetaminophen, atorvastatin, ibrutinib, sotorasib, and a PROTAC like ARV-471, you've internalized Chapter 35. The chemistry is now your tool.